What is the share price of SMS Pharmaceuticals Ltd (SMSPHARMA) today?
The share price of SMSPHARMA as on 13th June 2025 is ₹247.55. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The past returns of SMS Pharmaceuticals Ltd (SMSPHARMA) share are- Past 1 week: 2.07%
- Past 1 month: 4.47%
- Past 3 months: 29.70%
- Past 6 months: 0.14%
- Past 1 year: 18.42%
- Past 3 years: 212.37%
- Past 5 years: 349.27%
What are the peers or stocks similar to SMS Pharmaceuticals Ltd (SMSPHARMA)?
The peers or stocks similar to SMS Pharmaceuticals Ltd (SMSPHARMA) include:What is the dividend yield % of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The current dividend yield of SMS Pharmaceuticals Ltd (SMSPHARMA) is 0.15.What is the market cap of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹2269.05 Cr as of 13th June 2025.What is the 52 week high and low of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The 52-week high of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹398 and the 52-week low is ₹176.05.What is the PE and PB ratio of SMS Pharmaceuticals Ltd (SMSPHARMA) stock?
The P/E (price-to-earnings) ratio of SMS Pharmaceuticals Ltd (SMSPHARMA) is 32.82. The P/B (price-to-book) ratio is 4.23.Which sector does SMS Pharmaceuticals Ltd (SMSPHARMA) belong to?
SMS Pharmaceuticals Ltd (SMSPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy SMS Pharmaceuticals Ltd (SMSPHARMA) shares?
You can directly buy SMS Pharmaceuticals Ltd (SMSPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
SMS Pharmaceuticals Ltd
SMSPHARMA Share Price
247.553.28% (-8.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SMSPHARMA Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
SMSPHARMA Performance & Key Metrics
SMSPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 32.83 | 4.23 | 0.15% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.25 | 6.67 | 0.83% |
SMSPHARMA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SMSPHARMA Company Profile
SMS Pharmaceuticals Limited is engaged in manufacturing and sale of bulk drugs and active pharmaceutical ingredients (APIs), and their intermediates.
SUNPHARMA
PE Ratio
37.04
37.04
1Y Return
11.72%
11.72%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.02
23.02
1Y Return
2.38%
2.38%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
20.05
20.05
1Y Return
11.76%
11.76%
Buy Reco %
56.67
56.67
TORNTPHARM
PE Ratio
57.71
57.71
1Y Return
13.13%
13.13%
Buy Reco %
72.00
72.00
MANKIND
PE Ratio
49.54
49.54
1Y Return
6.30%
6.30%
Buy Reco %
81.25
81.25
SMSPHARMA Sentiment Analysis
SMSPHARMA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SMSPHARMA Stock Summary · June 2025
The company has demonstrated robust financial performance, with a remarkable 39% increase in Profit After Tax for FY '25, driven by strategic initiatives such as backward integration and a diversified product mix. Despite facing challenges like high inventory levels and pricing pressures, management remains optimistic about achieving a targeted 20% revenue growth and expanding EBITDA margins in FY '26, supported by a significant capital expenditure plan of INR 250 crores. The focus on high-volume APIs, particularly in the ibuprofen segment, is expected to enhance market share and profitability, with ambitious volume targets set to reach 5,000 tons. Overall, the company is well-positioned to capitalize on growth opportunities while navigating market dynamics effectively.
SMSPHARMA Stock Growth Drivers
SMSPHARMA Stock Growth Drivers
6Strong Financial Performance
The company reported a significant 39% growth in Profit After Tax (PAT) for FY '25,
Operational Milestones and Compliance
The company achieved notable operational milestones, including the launch of Asia's largest dedicated automated production
SMSPHARMA Stock Challenges
SMSPHARMA Stock Challenges
4High Inventory Levels
The company is currently facing challenges due to high inventory levels, which amount to INR
Debt and Financial Burden
The company has a significant debt of INR 311 crores, which incurs an annual interest
SMSPHARMA Forecast
SMSPHARMA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SMSPHARMA
SMSPHARMA
Income
Balance Sheet
Cash Flow
Annual Normal View
SMSPHARMA Income Statement
SMSPHARMA Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 439.58 | 465.07 | 468.31 | 417.06 | 566.62 | 525.07 | 526.96 | 713.73 | 788.97 | 788.97 | ||||||||||
Raw Materials | 325.03 | 294.32 | 307.19 | 259.50 | 313.27 | 387.95 | 299.72 | 425.26 | 643.76 | 643.75 | ||||||||||
| Power & Fuel Cost | 18.23 | 22.57 | 21.75 | 18.99 | 23.31 | 32.58 | 35.97 | 47.12 | ||||||||||||
| Employee Cost | 26.92 | 32.80 | 35.59 | 39.35 | 41.17 | 51.02 | 50.08 | 56.78 | ||||||||||||
| Selling & Administrative Expenses | 10.23 | 9.67 | 9.84 | 10.18 | 19.02 | 21.12 | 25.28 | 35.68 | ||||||||||||
| Operating & Other expenses | -17.42 | 9.97 | 0.40 | 3.90 | 45.27 | -87.41 | 56.46 | 27.66 | ||||||||||||
EBITDA | 76.59 | 95.74 | 93.54 | 85.14 | 124.58 | 119.81 | 59.45 | 121.23 | 145.21 | 145.22 | ||||||||||
| Depreciation/Amortization | 19.18 | 19.90 | 19.27 | 22.07 | 22.28 | 32.15 | 32.13 | 31.52 | 34.34 | 34.34 | ||||||||||
| PBIT | 57.41 | 75.84 | 74.27 | 63.07 | 102.30 | 87.66 | 27.32 | 89.71 | 110.87 | 110.88 | ||||||||||
| Interest & Other Items | 15.82 | 15.48 | 11.92 | 12.32 | 11.19 | 19.16 | 21.97 | 23.60 | 18.54 | 18.55 | ||||||||||
| PBT | 41.59 | 60.36 | 62.35 | 50.75 | 91.11 | 68.50 | 5.35 | 66.11 | 92.33 | 92.33 | ||||||||||
| Taxes & Other Items | 13.09 | 28.59 | 22.31 | 19.18 | 28.60 | 6.28 | 12.41 | 16.28 | 23.20 | 23.21 | ||||||||||
| Net Income | 28.50 | 31.77 | 40.04 | 31.57 | 62.51 | 62.22 | -7.06 | 49.83 | 69.13 | 69.12 | ||||||||||
| EPS | 3.37 | 3.75 | 4.73 | 3.73 | 7.38 | 7.35 | -0.83 | 5.89 | 8.16 | 8.17 | ||||||||||
| DPS | 0.20 | 0.25 | 0.25 | 0.25 | 0.30 | 0.30 | 0.30 | 0.40 | 0.40 | 0.40 | ||||||||||
| Payout ratio | 0.06 | 0.07 | 0.05 | 0.07 | 0.04 | 0.04 | — | 0.07 | 0.05 | 0.05 |
SMSPHARMA Company Updates
FY 2025FY 2025
Investor Presentation
Feb 12PDF
Nov 12PDF
SMSPHARMA Stock Peers
SMSPHARMA Past Performance & Peer Comparison
SMSPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| SMS Pharmaceuticals Ltd | 32.82 | 4.23 | 0.15% |
| Sun Pharmaceutical Industries Ltd | 37.04 | 6.03 | 0.95% |
| Cipla Ltd | 23.02 | 4.53 | 1.06% |
| Dr Reddy's Laboratories Ltd | 20.05 | 4.01 | 0.59% |
SMSPHARMA Stock Price Comparison
Compare SMSPHARMA with any stock or ETFCompare SMSPHARMA with any stock or ETF
SMSPHARMA
SMSPHARMA Holdings
SMSPHARMA Shareholdings
SMSPHARMA Promoter Holdings Trend
SMSPHARMA Promoter Holdings Trend
Increased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has increased by 1.59%
High Pledged Promoter Holding
Lower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
SMSPHARMA Institutional Holdings Trend
SMSPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SMSPHARMA Shareholding Pattern
SMSPHARMA Shareholding Pattern
SMSPHARMA Shareholding History
SMSPHARMA Shareholding History
Foreign Institutions
Mutual Funds Invested in SMSPHARMA
Mutual Funds Invested in SMSPHARMA
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 3 Mutual Funds holding SMS Pharmaceuticals Ltd
| Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.9343% | Percentage of the fund’s portfolio invested in the stock 0.17% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 91/112 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9721% | Percentage of the fund’s portfolio invested in the stock 5.29% | Change in the portfolio weight of the stock over the last 3 months 1.63% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 14/27 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0005% | Percentage of the fund’s portfolio invested in the stock 0.06% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 91/109 (-2) |
Compare 3-month MF holding change on Screener
smallcases containing SMSPHARMA stock
smallcases containing SMSPHARMA stock
Looks like this stock is not in any smallcase yet.
SMSPHARMA Events
SMSPHARMA Events
SMSPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SMSPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.49 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SMSPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SMSPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.15%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.49 every year
SMSPHARMA Upcoming Dividends
SMSPHARMA Upcoming Dividends
No upcoming dividends are available
SMSPHARMA Past Dividends
SMSPHARMA Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2024
Final
Final | Div/Share: ₹0.40
Dividend/Share
₹0.40
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 22, 2023
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2022
Cash Dividend
Ex DateEx DateSep 22, 2021
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2021
Cash Dividend
Ex DateEx DateMar 26, 2020
Interim
Interim | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Mar 26, 2020
SMSPHARMA Stock News & Opinions
SMSPHARMA Stock News & Opinions
Articles & Videos
Corporate
Board of SMS Pharmaceuticals recommends final dividend
SMS Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 30 May 2025, inter alia, have recommended the final dividend of Rs 0.4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
SMS Pharmaceuticals consolidated net profit rises 17.59% in the March 2025 quarter
Net profit of SMS Pharmaceuticals rose 17.59% to Rs 20.32 crore in the quarter ended March 2025 as against Rs 17.28 crore during the previous quarter ended March 2024. Sales rose 0.98% to Rs 248.20 crore in the quarter ended March 2025 as against Rs 245.80 crore during the previous quarter ended March 2024. For the full year,net profit rose 38.75% to Rs 69.14 crore in the year ended March 2025 as against Rs 49.83 crore during the previous year ended March 2024. Sales rose 10.36% to Rs 782.75 crore in the year ended March 2025 as against Rs 709.26 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales248.20245.80 1 782.75709.26 10 OPM %16.4413.67 -17.7616.44 - PBDT37.1629.65 25 126.6797.62 30 PBT28.5221.74 31 92.3466.11 40 NP20.3217.28 18 69.1449.83 39 Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
SMS Pharmaceuticals to announce Quarterly Result
SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 May 2025.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
SMS Pharmaceuticals' Unit VII receives WHO Geneva prequalification
SMS Pharmaceuticals announced that Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prequalification approval from the World Health Organisation (WHO) Geneva. The company added, This significant milestone enhances our global regulatory standing and enables the company to increase its presence in the global market for Anti-Retroviral (ARV) APIs. Commenting on this achievement, P. Vamsi Krishna, Executive Director, stated: 'The WHO Geneva prequalification reflects the company's strong compliance with stringent international regulatory standards, reinforcing its reputation for quality, reliability, and global competitiveness.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
SMS Pharma gains after Hyderabad facility completes USFDA inspection
According to an exchange filing, the inspection was conducted from 17 March to 21 March 2025 and concluded with one observation in Form 483. The observation was procedural in nature and does not relate to data integrity or product quality. The company will provide the necessary response to USFDA within the stipulated period. The Hyderabad facility has a manufacturing capacity of 120 KL, specializing in niche small-volume and high-value molecules. It holds multiple regulatory approvals, including USFDA, EU GMP, KFDA, ANVISA, PMDA, and CDSCO. P. Vamsi Krishna, executive director, stated, The successful completion of the USFDA inspection underscores our commitment to quality, compliance, and global regulatory standards. This is the 6th USFDA inspection for this facility, reflecting our team's dedication to maintaining the highest manufacturing practices. This milestone further strengthens our reputation as a trusted partner in the pharmaceutical industry, ensuring an uninterrupted supply of high-quality APIs to key international markets. The official announcement was made on Friday, 21 March 2025, after market hours. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. The company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 70 countries. The company's consolidated net profit surged 58.9% to Rs 18.24 crore in Q3 FY25 as against Rs 11.48 crore recorded in Q3 FY24. Revenue from operations rose 7.4% to Rs 173.35 in the quarter ended 31 December 2024. Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
SMS Pharma's Hyderabad facility completes USFDA inspection with 1 observation
According to an exchange filing, the inspection was conducted from 17 March to 21 March 2025 and concluded with one observation in Form 483. The observation was procedural in nature and does not relate to data integrity or product quality. The company will provide the necessary response to USFDA within the stipulated period. The Hyderabad facility has a manufacturing capacity of 120 KL, specializing in niche small-volume and high-value molecules. It holds multiple regulatory approvals, including USFDA, EU GMP, KFDA, ANVISA, PMDA, and CDSCO. P. Vamsi Krishna, executive director, stated, The successful completion of the USFDA inspection underscores our commitment to quality, compliance, and global regulatory standards. This is the 6th USFDA inspection for this facility, reflecting our team's dedication to maintaining the highest manufacturing practices. This milestone further strengthens our reputation as a trusted partner in the pharmaceutical industry, ensuring an uninterrupted supply of high-quality APIs to key international markets. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. The company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 70 countries. The company's consolidated net profit surged 58.9% to Rs 18.24 crore in Q3 FY25 as against Rs 11.48 crore recorded in Q3 FY24. Revenue from operations rose 7.4% to Rs 173.35 in the quarter ended 31 December 2024. The counter advanced 2.16% to end at Rs 217.90 on the BSE on Friday. Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
SMS Pharmaceuticals consolidated net profit rises 58.89% in the December 2024 quarter
Net profit of SMS Pharmaceuticals rose 58.89% to Rs 18.24 crore in the quarter ended December 2024 as against Rs 11.48 crore during the previous quarter ended December 2023. Sales rose 7.35% to Rs 173.35 crore in the quarter ended December 2024 as against Rs 161.48 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales173.35161.48 7 OPM %19.1617.96 - PBDT31.1324.54 27 PBT22.4416.53 36 NP18.2411.48 59 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals schedules board meeting
SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
SMS Pharmaceuticals consolidated net profit rises 20.20% in the September 2024 quarter
Net profit of SMS Pharmaceuticals rose 20.20% to Rs 14.10 crore in the quarter ended September 2024 as against Rs 11.73 crore during the previous quarter ended September 2023. Sales rose 18.07% to Rs 196.75 crore in the quarter ended September 2024 as against Rs 166.64 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales196.75166.64 18 OPM %15.9916.69 - PBDT28.1623.06 22 PBT19.5415.16 29 NP14.1011.73 20 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals to convene board meeting
SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 8.79%, vs industry avg of 9.02%
Over the last 5 years, market share decreased from 0.21% to 0.19%
Over the last 5 years, net income has grown at a yearly rate of 4.47%, vs industry avg of 15.29%